Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50-Day Moving Average of $4.80

Vistagen Therapeutics, Inc. (NASDAQ:VTGN)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.80 and traded as high as $5.36. Vistagen Therapeutics shares last traded at $4.89, with a volume of 321,688 shares.

Vistagen Therapeutics Stock Down 7.8 %

The stock has a 50 day simple moving average of $4.80 and a 200-day simple moving average of $4.41.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Tuesday, February 13th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.09. Vistagen Therapeutics had a negative net margin of 3,073.51% and a negative return on equity of 72.10%. The company had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.73 million. On average, sell-side analysts expect that Vistagen Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of Vistagen Therapeutics by 7.6% in the 1st quarter. BlackRock Inc. now owns 13,202,454 shares of the company’s stock valued at $1,646,000 after purchasing an additional 934,486 shares during the last quarter. State Street Corp lifted its position in Vistagen Therapeutics by 4.4% in the first quarter. State Street Corp now owns 6,432,023 shares of the company’s stock worth $802,000 after buying an additional 269,252 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Vistagen Therapeutics by 353.0% during the third quarter. Renaissance Technologies LLC now owns 3,762,374 shares of the company’s stock worth $572,000 after buying an additional 2,931,762 shares during the period. Geode Capital Management LLC increased its position in Vistagen Therapeutics by 5.4% during the first quarter. Geode Capital Management LLC now owns 3,449,805 shares of the company’s stock valued at $430,000 after acquiring an additional 177,189 shares during the last quarter. Finally, BVF Inc. IL bought a new stake in shares of Vistagen Therapeutics in the 4th quarter worth about $10,280,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.